For the secondary end points , the least-square mean absolute differences between groups all favored eliglustat , with a 1.22-g / dL increase in hemoglobin level ( 95 % CI , 0.57-1 .88 g/dL ; P < .001 ) , 6.64 % decrease in liver volume ( 95 % CI , -11.37 % to -1.91 % ; P = .007 ) , and 41.06 % increase in platelet count ( 95 % CI , 23.95 % -58.17 % ; P < .001 ) .